Temozolomide News and Research

RSS

New cancer drug begins clinical trial in human patients with rare brain tumor

A drug that spurs cancer cells to self-destruct has been cleared for use in a clinical trial of patients with anaplastic astrocytoma, a rare malignant brain tumor, and glioblastoma multiforme, an aggressive late-stage cancer of the brain.

28 Nov 2017

Preclinical studies show effectiveness of targeted therapy for glioblastoma

The targeted therapy onalespib has shown effectiveness in preclinical studies of glioblastoma by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

2 Nov 2017

Genome-wide molecular tests can guide treatment in recurrent glioblastoma, study shows

Several patients with recurring glioblastoma, a deadly brain cancer, survived for more than a year in a clinical trial believed to be the first to use comprehensive DNA and RNA sequencing of a patient's tumor to inform treatment for these patients in real-time.

27 Oct 2017

Arsenic trioxide could be powerful therapy to extend lives of certain glioblastoma patients

From Sherlock Holmes to Agatha Christie, arsenic is often the poison of choice in popular whodunits. But in ultra-low dosage, and in the right form, this naturally occurring chemical element can be a potent force against cancer.

17 Oct 2017

Japanese researchers find new way for increasing effectiveness of drug delivery to brain tumors

For a cancer drug to be successful, it needs to reach the malignant tumor site. Researchers in Japan have now found a way for increasing the effectiveness of drug delivery to certain types of brain tumors, by packing epirubicin, a known antitumor agent, in specially designed polymeric micelles.

13 Sep 2017

New compound takes positive step toward creating drug for melanoma

While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward creating a drug that can kill melanoma cancer cells without harming nearby healthy cells.

26 Jul 2017

UAB spinoff develops drug-resistant immunotherapy to combat solid tumors

The University of Alabama at Birmingham and two partner institutions have received a European patent for their novel approach to fighting cancer, an approach that is led by the UAB spinoff biopharmaceutical company Incysus Ltd.

5 May 2017

Vaccine-chemotherapy combination may improve survival for glioblastoma patients

A vaccine targeting cytomegalovirus (CMV) antigen pp65, combined with high-dose chemotherapy (temozolomide), improved both progression-free survival and overall survival for a small group of glioblastoma (GBM) patients.

17 Apr 2017

New clinical approach offers hope for patients with aggressive brain cancer

Being diagnosed with a malignant brain tumor is devastating news for patients and their loved ones. Whereas some types of tumor respond well to treatment, others such as glioblastomas - the most common and aggressive brain tumors - are known to recur and progress within short times from the diagnosis.

23 Mar 2017

Combined therapy extends survival of older patients with glioblastoma, clinical study shows

Treating older patients who have malignant brain cancer with the chemotherapy drug temozolomide plus a short course of radiation therapy extends survival by two months compared to treating with radiation alone, show clinical trial results published today in the New England Journal of Medicine.

15 Mar 2017

TGen scientists identify potent inhibitory compound for treatment against glioblastoma

A study led by scientists at the Translational Genomics Research Institute has identified "a potent inhibitory compound" in the elusive hunt for an improved treatment against glioblastoma, the most common and deadly type of adult brain cancer.

18 Jan 2017

Chemotherapy-induced senescent cells promote side effects and cancer relapse

Standard chemotherapy is a blunt force instrument against cancer - and it's a rare cancer patient who escapes debilitating side effects from systemic treatments that mostly affect dividing cells, both malignant and healthy, throughout the body.

17 Jan 2017

Localized chemotherapy may be effective way to keep immune system intact, animal study suggests

In experiments on mice with a form of aggressive brain cancer, Johns Hopkins researchers have shown that localized chemotherapy delivered directly to the brain rather than given systemically may be the best way to keep the immune system intact and strong when immunotherapy is also part of the treatment.

22 Dec 2016

Study addresses cost-effectiveness of checkpoint inhibitors for advanced melanoma in Hong Kong

Immunotherapy with pembrolizumab has been deemed a cost-effective first line treatment for advanced melanoma patients in Hong Kong, researchers report at the ESMO Asia 2016 Congress in Singapore.

17 Dec 2016

Four miRNAs may hold vital clue to disease progression in gliobastoma

Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich have developed a new method of predicting disease progression in gliobastoma patients who have undergone standard treatment.

14 Jun 2016

Giving chemotherapy after radiotherapy delays rare brain tumour growth

GIVING chemotherapy after radiotherapy delays further growth of a rare type of brain tumour, increasing the number of patients alive at five years from 44 per cent to 56 per cent.

6 Jun 2016

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.

25 May 2016

Small lipid nanocarrier may deliver chemotherapeutic drug more efficiently to brain tumor cells

Great discoveries do come in small packages. Few know that better than Ann-Marie Broome, Ph.D., who feels nanotechnology holds the future of medicine with its ability to deliver powerful drugs in tiny, designer packages.

23 May 2016

DelMar's VAL-083 receives FDA orphan drug designation for treatment of medulloblastoma

DelMar Pharmaceuticals, Inc., announced today that the FDA Office of Orphan Products Development (OOPD) has granted orphan drug designation for its lead product candidate, VAL-083, in the treatment of medulloblastoma.

15 Mar 2016

Expression of BIRC3 protein associated with poor survival, recurrent disease in GBM patients

Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with low survival rates, with newly diagnosed patients surviving a median of 14 months and recurrent patients surviving a median of only 3 to 9 months. New therapeutic targets and biomarkers for prognosis are urgently needed.

7 Mar 2016